7-chloro-2-ethyl-N-(4-(4-(4-fluorophenyl)piperazin-1-yl)benzyl)imidazo[1,2-a]pyridine-3-carboxamide | 1334718-21-6

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 二嗪烷类
• 英文名称: 7-chloro-2-ethyl-N-(4-(4-(4-fluorophenyl)piperazin-1-yl)benzyl)imidazo[1,2-a]pyridine-3-carboxamide
• 英文别名: 7-chloro-2-ethyl-N-{4-[4-(4-fluorophenyl)piperazin-1-yl]benzyl}imidazo[1,2-a]pyridine-3-carboxamide；7-chloro-2-ethyl-N-[[4-[4-(4-fluorophenyl)piperazin-1-yl]phenyl]methyl]imidazo[1,2-a]pyridine-3-carboxamide
• CAS: 1334718-21-6
• 化学式: C₂₇H₂₇ClFN₅O
• 分子量: 491.996
• InChiKey: LJGARRQSIYHDHV-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  6.1
• 重原子数：
  35
• 可旋转键数：
  6
• 环数：
  5.0
• sp3杂化的碳原子比例：
  0.26
• 拓扑面积：
  52.9
• 氢给体数：
  1
• 氢受体数：
  5

反应信息

• 作为产物：
  描述：

  丙酰乙酸乙酯 在 N-溴代丁二酰亚胺(NBS) 、 ammonium acetate 、 水 、 1-羟基苯并三唑 、 盐酸-N-乙基-Nˊ-(3-二甲氨基丙基)碳二亚胺 、 三乙胺 、 lithium hydroxide 作用下， 以 乙醚 、 乙醇 、 N,N-二甲基甲酰胺 为溶剂， 反应 8.0h， 生成 7-chloro-2-ethyl-N-(4-(4-(4-fluorophenyl)piperazin-1-yl)benzyl)imidazo[1,2-a]pyridine-3-carboxamide
  参考文献：
  名称：

  Lead Optimization of a Novel Series of Imidazo[1,2-a]pyridine Amides Leading to a Clinical Candidate (Q203) as a Multi- and Extensively-Drug-Resistant Anti-tuberculosis Agent

  摘要：

  A critical unmet clinical need to combat the global tuberculosis epidemic is the development of potent agents capable of reducing the time of multi-drug-resistant (MDR) and extensively-drug-resistant (XDR) tuberculosis therapy. In this paper, we report on the optimization of imidazo[1,2-a]pyridine amide (IPA) lead compound 1, which led to the design and synthesis of Q203 (50). We found that the amide linker with IPA core is very important for activity against Mycobacterium tuberculosis H37Rv. Linearity and lipophilicity of the amine part in the IPA series play a critical role in improving in vitro and in vivo efficacy and pharmacokinetic profile. The optimized IPAs 49 and 50 showed not only excellent oral bioavailability (80.2% and 90.7%, respectively) with high exposure of the area under curve (AUC) but also displayed significant colony-forming unit (CFU) reduction (1.52 and 3.13 log10 reduction at 10 mg/kg dosing level, respectively) in mouse lung.

  DOI：

  10.1021/jm5003606

文献信息

• Anti-Inflammation Compounds
  申请人：No Zaesung

  公开号：US20140155387A1

  公开（公告）日：2014-06-05

  The present invention refers to: a compound having the general formula (I), wherein n is 0, 1, 2 or; m is 0, 1, 2 or 3; o is 0, 1, 2 or 3; W, X, Y and Z are independently selected from CH, N or N-oxide; A is NR 4 , C═O, C═S, OP(O)(O), P═O, CH 2 , or a heteroarly selected from the group consisting of (a), (b), (c), (d), (e), (f), (g); V is C═O, O, S, CH 2 , or NR 5 ; as well as its use in treating inflammatory diseases such as asthma, COPD, inflammation post infection, arthritis, atherosclerosis, pain and dermatitis.

  本发明涉及一种具有通式（I）的化合物，其中n为0、1、2或；m为0、1、2或3；o为0、1、2或3；W、X、Y和Z分别独立地选自CH、N或N-氧化物；A为NR4、C═O、C═S、OP(O)(O)、P═O、CH2，或从（a）、（b）、（c）、（d）、（e）、（f）、（g）组成的群体中选择的杂环基；V为C═O、O、S、CH2或NR5；以及其在治疗哮喘、COPD、感染后炎症、关节炎、动脉粥样硬化、疼痛和皮炎等炎症性疾病中的用途。
• ANTI-INFECTIVE COMPOUNDS
  申请人：Institut Pasteur Korea

  公开号：EP2547678A1

  公开（公告）日：2013-01-23
• EP2547678B1
  申请人：——

  公开号：EP2547678B1

  公开（公告）日：2016-03-16
• Anti-Infective Compounds
  申请人：No Zaesung

  公开号：US20130065884A1

  公开（公告）日：2013-03-14

  The present invention relates to small molecule compounds and their use in the treatment of bacterial infections, in particular Tuberculosis.
• US8865734B2
  申请人：——

  公开号：US8865734B2

  公开（公告）日：2014-10-21